3,3-diphenylpropanenitrile | CAS:2286-54-6

We serve 3,3-diphenylpropanenitrile CAS:2286-54-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3,3-diphenylpropanenitrile

Chemical Name:3,3-diphenylpropanenitrile
CAS.NO:2286-54-6
Synonyms:3,3-diphenylpropanenitrile
2-Cyano-1,1-diphenylethane
3,3-diphenyl-propionitrile
Molecular Formula:C15H13N
Molecular Weight:207.27000
 
Physical and Chemical Properties:
Density:1.057
Melting point:86ºC
Boiling point:174ºC
Flash point:194.4ºC
Index of Refraction:1.574
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 3,3-diphenylpropanenitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,3-diphenyl-propionitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,3-diphenylpropanenitrile Use and application,3,3-diphenylpropanenitrile technical grade,usp/ep/jp grade.


Related News: The insulin-only and bihormonal configurations may be helpful in diabetes.1,2-Ethanedithiol manufacturer “Traditional medicine is a treasure of Chinese civilization embodying the wisdom of the nation and its people,” Xi said at the meeting in Beijing.3-Chloro-1-phenylpropan-1-ol supplier The new restrictions on foreign nationals begin on February 3, Prime Minister Jacinda Ardern announced in a press release Sunday.2-Amino-3,5-dichloropyridine vendor With the onset of the DMF system for APIs, the concentration of the API industry will further increase.The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.